AI-Powered Volumetric Biomarkers

NeuroQuant

LesionQuant

PETQuant

  • Clinical in vivo quantitative MRI biomarkers
  • Personalized brain structure segmentation
  • Completely automated system – integrates with PACS
  • Available for ages 3 years to 100
  • Brain structure volumes compared to age and gender norms
  • Longitudinal evaluation on a single report
  • Easy workflow integration
[[[["field10","equal_to","United States"]],[["show_fields","field9"]],"and"],[[["field10","equal_to","Canada"]],[["show_fields","field14"]],"and"]]
1

Meet at RSNA 2019
‚Äč
McCormick Place - Chicago, IL 

Product InterestSelect all that apply
keyboard_arrow_leftPrevious
Nextkeyboard_arrow_right

FDA cleared, CE marked, and approved for clinical use in Brazil, Australia and South Korea.

Learn how AI-powered MRI post processing can support your clinical evaluation of Alzhiemer’s disease, MCI, epilepsy, multiple sclerosis, traumatic brain injury, and other neurodegenerative conditions.

*PETQuant is currently for research use only.